Oncolytic Virus
Oncolytic Virus - Related Videos
12:08
Ex Vivo Infection of Live Tissue with Oncolytic Viruses
0 Views •
Cited by 22 •
2011
Oncolytic viruses are promising for cancer therapeutics. The ability to ascertain the infectability of live tissue specimens obtained from patients prior to treatment is a unique advantage of this therapeutic approach. This protocol describes how to process tissues for ex vivo infection with oncolytic virus and subsequent viral quantification.
03:02
Oncolytic Virus Purification from Infected Mammalian Cells
0 Views •
2026
Source: Nguyen, H., et al. Growth, Purification, and Titration of Oncolytic Herpes Simplex Virus. J. Vis. Exp. (2021)This video demonstrates the purification of an oncolytic virus from infected mammalian cell cultures using nuclease treatment, sequential centrifugation, membrane filtration, and sucrose cushion centrifugation.
04:46
Targeting Liver Tumors with Oncolytic Viruses via the Hepatic Artery
0 Views •
2025
The video demonstrates locoregional delivery of oncolytic viruses through hepatic arterial injection as a therapeutic approach for hepatocellular carcinoma. These viruses selectively replicate in tumor cells, inducing cell lysis and releasing tumor cell-associated antigens. This process triggers immunogenic cell death, inducing an anti-tumor response.
08:55
Transarterial Administration of Oncolytic Viruses for Locoregional Therapy of Orthotopic HCC in Rats
0 Views •
Cited by 3 •
2016
Oncolytic virotherapies are under development as novel therapeutics for the treatment of hepatocellular carcinoma (HCC). Here we describe a method for locoregional therapy of HCC via hepatic arterial administration of oncolytic virus.
03:01
Propagation and Harvesting of Oncolytic Herpes Simplex Virus in Mammalian Cells
0 Views •
2026
Source: Nguyen, H., et al. Growth, Purification, and Titration of Oncolytic Herpes Simplex Virus. J. Vis. Exp. (2021).This video demonstrates the propagation and harvesting of oncolytic herpes simplex virus in mammalian cell cultures, highlighting viral entry, replication, and the recovery of virus-loaded cells. It further shows methods for preserving infected cells for downstream processing.
FAQs
Selectivity depends on whether tumor cells are susceptible to viral entry and replication, while healthy tissue is less affected. Viruses may be engineered or naturally selected to favor this difference. The balance between tumor targeting and normal-tissue protection is therefore a central determinant of therapeutic design and clinical impact.
When infected tumor cells undergo lysis, they release tumor-associated antigens and danger signals. These materials can alert and stimulate the immune system, extending activity beyond the cells directly infected by the virus. This creates a potential connection between localized viral destruction and immune responses against neighboring malignant cells.
Clinical impact depends on several interacting factors: the virus must target tumor cells, reach them through effective delivery, and replicate in susceptible malignant tissue. The resulting immune response can either support broader antitumor activity or affect treatment behavior. Conditions within the tumor microenvironment also influence the overall outcome.
Its potential effects include both direct destruction and immune stimulation. Viral replication can lyse susceptible cancer cells, while released antigens and danger signals may activate responses against nearby malignant cells. This two-part activity distinguishes the platform from an approach considered only in terms of direct tumor-cell damage.
A standalone approach may be studied when the therapeutic goal is to combine direct tumor-cell lysis with the immune stimulation generated by viral activity. Its suitability still depends on tumor targeting, delivery, immune responses, and the tumor microenvironment. These factors help determine whether the platform can produce a meaningful treatment effect on its own.
Combination treatment is being studied because viral tumor destruction can release antigens and danger signals that stimulate the immune system. Immunotherapy or another anticancer strategy may be evaluated alongside that activity rather than replacing it. The purpose is to investigate whether complementary effects improve the overall response compared with using the virus alone.
In medicine, oncolytic virotherapy provides a therapeutic platform for studying how selective viral activity, tumor-cell lysis, and immune responses can be integrated in cancer treatment. Research examines both standalone and combination approaches while accounting for delivery and the tumor microenvironment. These investigations help clarify which conditions support the greatest clinical impact.